Kushenin combined with nucleos(t)ide analogues for chronic hepatitis B: a systematic review and meta-analysis
Objective: To evaluate the efficacy and safety of kushenin (KS) combined with nucleoside analogues (NAs) for chronic hepatitis B (CHB).Methods: Randomized controlled trails (RCTs) of KS combined with NAs for CHB were identified through 7 databases.Frequencies of loss of serum HBeAg, HBeAg seroconversion, undetectable serum HBV-DNA, ALT normalization and adverse events at 48 weeks were abstracted by two reviewers.The Cochrane software was performed to assess the risk of bias in the included trials.Data were analyzed with Review Manager 5.3 software.Results: 18 RCTs involving 1684 subjects with CHB were included in the analysis.KS combined with NAs including lamivudine (LAM), entecavir (ETV), adefovir dipivoxil (ADV), telbivudine (TLV) showed different degree of improvement in CHB indices.KS combined with NAs increased the frequency of loss of serum HBeAg, HBeAg seroconversion, undetectable HBV-DNA levels and ALT normalization compared with single agents.It also decreased serum ALT and AST level after one-year treatment.Although KS combined with TLV did not show a significant difference in CHB indices.The side-effects of KS combined with NAs were light and low frequency.Conclusion: KS combined with NAs improves the efficacy of NAs in CHB.
Kushenin nucleoside analogues chronic hepatitis B meta-analysis efficacy
CHEN Zhe SHI Zhilong XIAO Xiaohe Zhao Yanling MA Xiao CHEN Chang WEI Shizhang LU Xiaohua YANG Zhirui HUANG Yinqiu WU Mingquan
China Military Institute of Chinese Medicine, 302 Hospital of People”s Liberation Army, Beijing, 100 China Military Institute of Chinese Medicine, 302 Hospital of People”s Liberation Army, Beijing, 100
国内会议
世界中医药学会联合会中医药抗病毒研究专业委员会第一届学术年会
烟台
英文
363-380
2015-07-01（万方平台首次上网日期，不代表论文的发表时间）